еНаука - преглед

Преглед према Аутор Poddubskaya, Elena

Приказ резултата 1 до 5 од 5
ГодинаНасловАутор(и)Тип резултатаМп-кат.
2021Bevacizumab biosimilar (MB02) and reference bevacizumab in patients with stage IIIB/IV non-squamous non-small cell lung cancer (NSCLC) (STELLA study): Multiple Imputation analysis.Trukhin, Dmytro; Poddubskaya, Elena; Andric, Zoran G  ; Bondarenko, Igor N; Shevnia, Serhii; Zaric, Bojan  ; Bellala, Ravishankar; Charoentum, Chaiyut; Perez, Luis; Bullo, Felicitas;
Garcia, Fernanda;
Конференцијски рад
Мп категорија ће бити приказана накнадно.
2020Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study.Millan, Susana; Trukhin, Dmytro; Kolesnik, Oleksii; Poddubskaya, Elena; Andric, Zoran G  ; Bondarenko, Igor N; Shevnia, Serhii; Bullo, Felicitas; Sarnago, CristinaКонференцијски рад
Мп категорија ће бити приказана накнадно.
2023Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301 (✓)Cho, Byoung Chul; Ahn, Myung-Ju; Kang, Jin Hyoung; Soo, Ross A.; Reungwetwattana, Thanyanan; Yang, James Chih-Hsin; Cicin, Irfan; Kim, Dong-Wan; Wu, Yi-Long; Lu, Shun;
Lee, Ki Hyeong; Pang, Yong-Kek; Zimina, Anastasia; Fong, Chin Heng; Poddubskaya, Elena; Sezer, Ahmet; How, Soon Hin; Danchaivijitr, Pongwut; Kim, YuKyung; Lim, Yeji; An, Taewon; Lee, Hana; Byun, Hae Mi; Zaric, Bojan  ;
Научни чланак
21aM21a - Рад у међ. часопису изузетних вредности
2018Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancerVan, Cutsem Eric; Hidalgo, Manuel; Canon, Jean-Luc; Macarulla, Teresa; Bazin, Igor; Poddubskaya, Elena; Manojlovic, Nebojsa S  ; Radenkovic, Dejan V; Verslype, Chris; Eric, Raymond;
Cubillo, Antonio; Schueler, Armin; Zhao, Charles; Hammel, Pascal;
Научни чланак
21M21 - Рад у врхунском међ. часопису
2015Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.Van, Cutsem Eric; Hidalgo, Manuel; Bazin, Igor; Canon, Jean-Luc; Poddubskaya, Elena; Manojlovic, Nebojsa S  ; Milella, Michele; Radenkovic, Dejan V; Verslype, Chris; Guo, Wei;
Damstrup, Lars; Hammel, Pascal;
Конференцијски рад
Мп категорија ће бити приказана накнадно.